Nuvama advises investors to buy shares in Fortis Healthcare, predicting the stock could reach ₹1,145. Investors should consider purchasing Fortis shares based on Nuvama's recommendation.

Strong Q4 performance by Fortis Healthcare has led brokerages to predict an upward potential of up to 18%. This optimistic outlook suggests a positive momentum for the company's shares moving forward.

Goldman Sachs maintains a neutral stance towards Fortis Healthcare, predicting shares to reach approximately Rs. 950. Investors may want to closely watch the company's performance before making any decisions.

Citi maintains a bullish outlook for Fortis Healthcare, setting its target price at ₹1,120, suggesting continued investment potential in the company.

Fortis Healthcare aims to expand its capacity significantly over the next three years, with an addition of 2,000 beds scheduled by 2027, and 500 beds projected to become operational by then.

Fortis Healthcare, a leading healthcare provider, aims to expand its presence in India through acquisitions, brownfield projects, and focusing on specialty care in both northern and southern regions of the country. The strategy has proven effective, with a 17.3% increase in revenue for FY26, reaching INR 9,128 crore. This growth was particularly notable in diagnostics (up 21%) and international patient revenue (up 18.5% to INR 639 crore).

The Delhi High Court has found Fortis Healthcare responsible for a share slip incident, stating that the company cannot avoid accountability by passing it onto a third party.

Fortis Healthcare shows robust performance even amidst fresh hospital costs, attributed to effective growth strategies detailed by CFO Vivek Gopal.

Fortis Healthcare intends to expand its capacity by adding 1,800 beds, aiming for a 25% EBITDA margin by the fiscal year 2028. This move could potentially enhance the healthcare provider's overall profitability.

Fortis Healthcare reports a significant 45% increase in Q4 profit, reaching ₹265.9 crore, largely due to reduced exceptional losses. The company's revenue also grew by 17.8%, reaching ₹2,364.7 crore, and the EBITDA margin improved from 21.7% to 22.5%. Shareholders are proposed a final dividend of ₹1 per share.

Fortis Healthcare has announced a significant rise in its Q4 EBITDA, reaching ₹5.3B compared to ₹4.4B the previous year. The improvement also extended to the EBITDA margin, which increased from 21.9% YoY to 22.5%.

Fortis Healthcare has declared a final dividend of INR 1 per share for the financial year 2026, subject to regulatory approvals. Additionally, the board appointed Jitender Navneet & Co. as cost auditors and updated its Corporate Social Responsibility (CSR) policy for the upcoming fiscal year 2027.

The Competition Commission of India (CCI) has finally concluded a decade-long antitrust case involving 12 hospitals and Fortis Healthcare. According to reports from CNBC TV18, Fortis Healthcare has received the order regarding this matter.

The board of Fortis Healthcare will convene on May 22, 2026, to discuss and approve their audited financial results, potentially deciding on a final dividend distribution. Trading in their securities will remain halted until May 24, following the results announcement.

Fortis Healthcare has made a significant uptrend by breaking out of a rounded bottom pattern, indicating potential for further growth, as seen by the increase in trading volume and higher highs and lows. This could signal an upward momentum for the company's shares.

Ajit Mishra of Religare Broking suggests investors consider Bharat Forge, Fortis Healthcare, and Delhivery for short-term profits due to favorable technical trends. Bharat Forge is experiencing a bullish surge, while Delhivery aims towards ₹524. Fortis Healthcare has surpassed resistance, with a potential price target of ₹1,020.

Under IHH's restructuring since FY19, Fortis Healthcare significantly improved its governance and operations, achieving a robust 33% EBITDA CAGR (FY18-26E). Valued on a SoTP basis, their hospital business is priced at 30x and diagnostics at 23x EV/EBITDA, matching industry peers Max Healthcare and Apollo Hospitals' valuations.

Infosys may face challenges in the short term due to intense competition and pricing pressures in the AI sector, according to MOFSL's Khemka. On a positive note, Khemka remains optimistic about Fortis Healthcare's turnaround and is bullish on investments in renewable energy companies like ACME Solar.

Motilal Oswal has initiated a 'Buy' recommendation for Fortis Healthcare, indicating a positive outlook and setting a target price of ₹1,100.

Fortis Healthcare successfully lists NCDs worth ₹1,550 crore on the Bombay Stock Exchange, marking no payment defaults. CRISIL has boosted Fortis's credit rating from AA to AAA, signaling a stable financial outlook.

IHH, a major player in healthcare services, is planning to boost its control over Fortis Health by purchasing additional shares, aiming to raise their stake to half of the company.

IHH Healthcare is increasing its investments in India by channeling funds through Fortis Healthcare, according to reports on CNBC TV18. This move indicates a strengthened commitment from IHH Healthcare towards the Indian healthcare sector.

Fortis aims to increase its ownership from 31% to 50%, and plans to boost bed capacity to 10,000 by 2030. IHH Healthcare's CEO has confirmed their readiness to provide capital for significant M&A deals, such as hospital acquisitions.

IHH Healthcare intends to grow in India by leveraging acquisitions of Fortis and Gleneagles, having resolved legal complications. This move will bolster their existing presence within the Indian healthcare market.

Endurance Tech remains a Buy recommendation by Citi, yet the target price is revised down to Rs 2,900 due to demand concerns. The financial services firm Fortis Healthcare expects an EBITDA margin of 22-25% by FY26. Jefferies predicts a 74% growth potential for Aavas Financiers, setting a target price at Rs 1,875. However, Morgan Stanley expresses caution and prefers Aptus and Home First Finance over Aavas Financiers.